Tesamorelin & Ipamorelin Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Tesamorelin & Ipamorelin Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

FDA-approved synthetic GHRH analog that stimulates pulsatile GH release; indicated to reduce excess visceral fat in HIV-associated lipodystrophy.

Tesamorelin binds the GHRH receptor (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase via Gs coupling and elevating intracellular cAMP. This drives both synthesis and pulsatile secretion of endogenous growth hormone (GH), preserving hypothalamic-pituitary feedback regulation. Circulating GH subsequently stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1), which mediates downstream metabolic effects including visceral lipolysis and promotion of lean body mass. Because the peptide acts upstream at the pituitary rather than supplying exogenous GH directly, physiological pulsatility and axis feedback are maintained.

Molar mass

5136 g/mol

Synthetic pentapeptide GHS-R1a agonist that triggers pulsatile GH release with high selectivity; minimal cortisol or prolactin co-elevation. Research use only.

Ipamorelin binds and activates GHS-R1a (the ghrelin receptor), a Gq/11-coupled GPCR expressed predominantly on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Receptor engagement activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone. Ipamorelin acts synergistically with endogenous GHRH to amplify pulsatile GH release while also partially suppressing somatostatin tone in the hypothalamus. A key pharmacological distinction from other GHRPs is its high receptor selectivity: at physiological concentrations it does not meaningfully activate adrenocortical or lactotroph pathways, so cortisol and prolactin co-elevation are minimal compared with GHRP-2 or GHRP-6.

Molar mass

711.9 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PMID 41545261. — Anchoring systematic review/meta-analysis of tesamorelin RCTs (single-agent; not the blend).
• Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012. PMID 22298602. — COMPONENT-LEVEL (tesamorelin), not blend-level.
• Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy (PMC3218714). — COMPONENT-LEVEL (tesamorelin), not blend-level.
• Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID 41966639. — Reviews regulatory status of tesamorelin, ipamorelin, CJC-1295 and other secretagogues; flags unapproved marketing. Component-level context, not a blend study.
• Ipamorelin — Wikipedia — Aggregator; notes ipamorelin was investigated in Phase II by Helsinn Therapeutics for postoperative ileus and discontinued for lack of efficacy; currently marketed only as a research peptide.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous

Tesamorelin: single- and multiple-dose PK characterized in healthy subjects and HIV-infected patients (FDA-approved, 2 mg SC). Ipamorelin: SC administration studied in male rats (Johansen 1998, PMID 9879640); no published human SC PK for ipamorelin was located. The tesamorelin+ipamorelin blend itself has no published human trial by any route.

Bioavailability: Tesamorelin absolute SC bioavailability <4% in healthy adults; mean elimination half-life ~8 min after a single SC 1.4 mg dose (confirmed against the FDA label/DailyMed SPL). Ipamorelin SC PK is characterized in rats only; no human SC PK for ipamorelin was located this pass.

SC is the FDA-labeled route for EGRIFTA/EGRIFTA SV (tesamorelin). Ipamorelin SC data are animal-level. The combination blend's SC use is a commercial/community packaging pattern, not a clinically validated finding.

Ipamorelin: dose-escalation human PK/PD study (Gobburu et al. 1999, healthy male volunteers). Tesamorelin: IV is not a labeled or human-studied route in the sources checked this pass.

Bioavailability: Ipamorelin IV showed dose-proportional PK: terminal half-life ~2 h, clearance 0.078 L/h/kg, Vss 0.22 L/kg; GH peak at 0.67 h, SC50 214 nmol/L, maximal GH production 694 mIU/L/h — confirmed against the primary Pharmaceutical Research 1999 article.

Only ipamorelin has published human IV PK/PD among these two components. Tesamorelin is not IV-studied per its FDA label; blend IV use is not studied.

Ipamorelin: intranasal absorption compared across routes in male rats (Johansen 1998). Tesamorelin: not studied intranasally in the sources checked this pass.

Bioavailability: Johansen 1998 (Xenobiotica, PMID 9879640) compared ipamorelin and related GHRPs across routes in rats with emphasis on nasal absorption; specific nasal-bioavailability figures were not extractable from the abstract.

Intranasal ipamorelin data are rat-level only; no human intranasal PK was located. Not a route studied for the blend.

Neither tesamorelin nor ipamorelin has an established oral human PK study in the sources checked this pass; oral delivery is discussed only as mechanistic/instability reasoning.

Bioavailability: Tesamorelin (~5,135 Da peptide) is subject to gastric proteolysis, intestinal enzymatic degradation, epithelial tight-junction impermeability, and hepatic first-pass metabolism; oral bioavailability is described as extremely low (<1%) only in secondary discussion, with no primary human oral PK study located for either peptide.

Oral STABILITY (not demonstrated absorption) is the relevant concern: peptide bonds are labile to gastric acid/proteases. No oral route is studied or approved for either component or the blend.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $7.40 · median $8.40 · p75 $11.25 · 8 researched vendors

Legit, COA-backed band: $7.50–$15.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$68

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

No independent-lab aggregate purity report specific to a combined tesamorelin+ipamorelin blend product was located. Component-level, not blend-level: Janoshik Analytical batch reports (via Panda Peptides' public COA hub) show single-component tesamorelin at 99.197% HPLC purity (10mg batch PP2602-039B) and single-component ipamorelin at 99.524% HPLC purity, Feb–May 2026.

Independent labs cited for this compound

No FDA recall or market withdrawal was found specifically targeting a 'Tesamorelin & Ipamorelin Blend' product, or targeting Egrifta/Egrifta WR (tesamorelin) individually.

Buyer red-flag checklist

• No FDA-approved drug application exists for a 'Tesamorelin & Ipamorelin Blend'; tesamorelin alone is approved (as Egrifta/Egrifta WR) for a single narrow indication, and that approval does not extend to the blend.
• Ipamorelin has never been FDA-approved for any indication and remains listed under interim 503B Category 2 (added 2023-09-29) as of this overlay's asOf date — its separate 503A nomination was withdrawn, but that is not the same as a full Category-2 clearance.
• No published randomized controlled trial or PK study exists for tesamorelin and ipamorelin administered together; all trial/PK evidence is component-level.
• Tesamorelin is cited (by a vendor buying guide, not an independent lab investigation) as a frequent counterfeit-substitution target — cheaper sermorelin sold as tesamorelin — which a blend format makes harder to catch without per-component mass-spec testing.
• No published independent lab test of a co-formulated tesamorelin+ipamorelin vial was located; purity data exists only for the separate components.
• FDA denied approval of Theratechnologies' F8 tesamorelin reformulation in a January 2024 Complete Response Letter (unrelated to the RUO market); the F8 formulation was subsequently approved in April 2025 as EGRIFTA WR, with EGRIFTA SV continuing unaffected throughout.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No aggregate underdosing/mislabeling prevalence figure for a combined tesamorelin+ipamorelin blend was located in independent-lab test databases this pass; no co-formulated blend batch report was found at all.

• FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.') authorizes DWPE via a firm-specific Red List; it does not name tesamorelin, ipamorelin, or this blend by name. Because ipamorelin has no FDA-approved drug application, an unapproved research-peptide shipment could in principle be detained under 66-41's general authority if the importing firm is red-listed — but no primary source establishes 66-41 targeting this pairing by name, and an RUO label is not itself an importation exemption.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Tesamorelin is named on the WADA 2026 Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a GHRH analogue, prohibited at all times (in- and out-of-competition). Ipamorelin, as a GHS/ghrelin-mimetic secretagogue, falls under the same S2 category by class description. No product-level schedule exists for a named 'tesamorelin & ipamorelin blend.'

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-selection bias toward positive-outcome reports.
• Vendor-affiliated / promotional subreddits and blogs can inflate apparent positive sentiment.
• Anecdotal self-reports without independent lab verification of the product actually used.
• Wide dosing variability across posters makes side-effect attribution unreliable.
• Blend-ratio confusion (5:1 vs 2:1 vs 1:1 tesamorelin:ipamorelin) conflates dosing-format discussion with efficacy claims.
• The single directly-linkable adverse report found (a Reddit r/Peptidesource ER-visit account) names a THREE-peptide tesamorelin/CJC-1295/ipamorelin stack, not this two-peptide blend specifically — reported here as a reception-mix input, not a blend-specific measured event.

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only two-peptide blend of the GHRH analog Tesamorelin and the selective growth hormone secretagogue Ipamorelin. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet